Texas Oncology

Association

Location: Dallas, TX

ISNI: 0000000404282340

ROR: https://ror.org/02ketev28

Show on Map:

Publications

(7)

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. (2025) Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, et al. Journal article Matching adjusted indirect comparison of PFS & OS comparing ribociclib plus letrozole vs palbociclib plus letrozole as first-line treatment of HR+/HER2-ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2 (2022) Jhaveri K, O'Shaughnessy J, Fasching P, Cardoso F, Tolaney S, Hamilton E, Sharma VK, et al. Conference contribution Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy (2022) Fasching P, Huang M, Haiderali A, Xue W, Pan W, Karantza V, Yang F, et al. Conference contribution COST EFFECTIVENESS OF PEMBROLIZUMAB COMBINED WITH CHEMOTHERAPY VS. CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC TNBC THAT EXPRESSES PD-L1 IN THE UNITED STATES (2022) Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou J, Hu PH, et al. Conference contribution High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE (2021) Harbeck N, Johnston S, Fasching P, Martin M, Toi M, Rastogi P, Song C, et al. Conference contribution Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer (2019) Fasching P, Huang M, Cortes J, Zhao J, O'Shaughnessy J, Hu P, Haiderali A, et al. Conference contribution Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma (2019) Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S Journal article, Review article